Clinical Trials Logo

Metabolic Diseases clinical trials

View clinical trials related to Metabolic Diseases.

Filter by:

NCT ID: NCT04556487 Completed - Metabolic Disease Clinical Trials

Turkish Affordances in the Home Environment for Motor Development-Infant Scale (AHEMD-IS)

Start date: October 1, 2020
Phase:
Study type: Observational

Environment which children live and grown is very important for the all development stages. In Turkey there is no measurement for home environment evaluation so our aim is to investigate the Psychometric Properties of the Turkish version of Affordances in the Home Environment for Motor Development-Infant Scale (AHEMD-IS) in a sample of Turkısh children.

NCT ID: NCT04552574 Recruiting - Sarcopenia Clinical Trials

Randomized Clinical Trial of HMR(Home Meal Replacement)-Type Omega-3-balanced-diet

Start date: August 19, 2020
Phase: N/A
Study type: Interventional

Investigate whether HMR(Home meal replacement)-type omega-3-balanced-diet can improve clinical laboratory values related to chronic metabolic diseases through reducing lipids and chronic inflammation, and can prevent muscle loss.

NCT ID: NCT04539340 Completed - Metabolic Diseases Clinical Trials

A Multi-cohort Study of the Tolerance, Safety, and Pharmacokinetics of GNR-055 in Healthy Volunteers

Start date: February 28, 2020
Phase: Phase 1
Study type: Interventional

It is a phase I open-label single-dose, dose-escalation cohort study to evaluate of the tolerance, safety, and pharmacokinetics of GNR-055 in healthy volunteers

NCT ID: NCT04531267 Not yet recruiting - Hypertension Clinical Trials

Ratio of Dietary Calcium to Magnesium on Cardiovascular Risk

Start date: January 2021
Phase: N/A
Study type: Interventional

Although the epidemiological studies indicate how magnesium and calcium may interact to affect cardiovascular risk, current clinical trials have not elucidated the associations, particularly among hypertensive patients. To address the research gap, we have to examine how magnesium may influence cardiovascular profile of hypertensive patients via the modification of calcium homeostasis. Meanwhile, large-scale cohorts in China suggested keeping dietary calcium: magnesium ratio within 2.3 can reduce the risk of cardiovascular mortality. The results indicate the potential for individualized nutrition. This study will recruit uncontrolled hypertensive patients taking single drug and investigate whether calcium-magnesium combined supplements help to control their blood pressure. In standardized manner, subjects in the intervention group and the control group (each with 21 subjects) will be assessed for their dietary calcium and magnesium intake in the previous three months, so that researchers can provide calcium and/or magnesium supplements to maintain a calcium/magnesium ratio as 2.3. The effect of supplementation will be evaluated by the blood pressure changes in the 12th week of intervention.

NCT ID: NCT04529473 Completed - Metabolic Syndrome Clinical Trials

Efficacy and Safety of 12-weeks Supplementation of Eubacterium Hallii on Insulin Sensitivity and Glycaemic Control

Start date: February 3, 2021
Phase: N/A
Study type: Interventional

This 12 week placebo-controlled study evaluates the efficacy and safety of E. hallii supplementation.

NCT ID: NCT04528446 Recruiting - Bone Fracture Clinical Trials

The Impact of Glomerular Disorders on Bone Quality and Strength

BoneGN
Start date: June 14, 2019
Phase:
Study type: Observational

The primary objectives of this study are to: (1) determine the impact of glomerular disease on bone strength and (2) investigate the pathophysiologic underpinnings of impaired bone strength in glomerular disease.

NCT ID: NCT04528355 Recruiting - Clinical trials for Primary Immunodeficiency (PID)

Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC

PRO-RIC
Start date: August 20, 2020
Phase:
Study type: Observational

This is a data collection study that will examine the general diagnostic and treatment data associated with the reduced-intensity chemotherapy-based regimen paired with simple alemtuzumab dosing strata designed to prevented graft failure and to aid in immune reconstitution following hematopoietic stem cell transplantation.

NCT ID: NCT04518605 Completed - Clinical trials for Overweight and Obesity

Breakfast for Young Females

NyStart2
Start date: August 15, 2020
Phase: N/A
Study type: Interventional

Investigators will test the health effects of eating a dairy-based protein-rich breakfast or isocaloric breakfast and performing regular physical exercise training for 12 weeks in young overweight women (2 x 2 factorial design). Measurements of body composition, physical fitness, metabolic health parameters, faeces and urine metabolites, and food diary will be collected.

NCT ID: NCT04488432 Completed - Metabolic Syndrome Clinical Trials

Endocrine, Bone And Metabolic Disorders In Adults After Allogeneic Stem-cell Transplant

ENDOCALLOGREFF
Start date: November 27, 2019
Phase:
Study type: Observational

Allogeneic hematopoietic stem cell transplantations (allo-HSCT) is often indicated in malignant hematologic diseases. Conditioning regimens, used to reduce the tumor burden and to prevent transplant rejection, are based on chemotherapy alone or combined with total body irradiation (TBI). Endocrine complications are frequent transplant-related side effects. Investigators have been well described in children studies but less in adulthood. The objective of this study is to assess retrospectively endocrine, bone and metabolic disorders in adult patients, 12 months after allo-HSCT.

NCT ID: NCT04485351 Recruiting - Diabetes Mellitus Clinical Trials

Assessing the Impact of the COVID-19 Lockdown on Metabolic Control and Access to Health Care in Patients With Diabetes

CONFI-DIAB
Start date: July 2020
Phase:
Study type: Observational

The outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the COVID-19 (Coronavirus Disease-2019) in December 2019 has led to an unprecedented international health situation. Exceptional measures have been taken by public authorities worldwide in order to slow the spread of the virus and prevent healthcare systems from becoming overloaded. In France, a national lockdown has been established during approximately 2 months to increase social distancing and restrict population movements. Hospital routine care appointments have been cancelled, in order to reallocate medical resources towards COVID-19 units and limit contacts between patients within hospitals or waiting rooms. While the virus itself, the disease and potential treatments are currently extensively studied, little data are available on the effect of these public health decisions on the management of a chronic condition such as diabetes. The French regional CONFI-DIAB study aims at assessing the collateral impact of routine care cancellation during the national lockdown due to COVID-19 in patients with a chronic condition such as diabetes. Special attention will be given to metabolic control and access to health care. This cross-sectional study should provide information on the consequences of a global lockdown and the associated routine care cancellation on the management of diabetes, and inform future decision making in the event of a new pandemic.